Vanta Bioscience Limited Returns to Profitability in FY2026

Revenue from Operations ₹1.8164 crore (₹181.64 lakh) | Net Profit ₹0.1198 crore (₹11.98 lakh)

Reader Takeaway: Financial turnaround achieved; revenue growth supports profitability, leadership continuity assured.

What just happened

Vanta Bioscience Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company has successfully transitioned from a net loss of ₹2.6595 crore in FY2025 to a net profit of ₹0.1198 crore in FY2026. Revenue from operations also saw a substantial increase, rising to ₹1.8164 crore from ₹1.1274 crore in the previous year.

Why this matters

This financial turnaround is significant for shareholders, indicating improved operational efficiency and market performance. The move from a loss to a profit, coupled with a revenue jump of approximately 61%, suggests a positive trajectory for the company. The auditors' unmodified and unqualified opinion adds credibility to these financial results.

The backstory

In the previous fiscal year, FY2025, Vanta Bioscience reported a net loss of ₹2.6595 crore. This year's results mark a considerable improvement, demonstrating the company's ability to recover and achieve profitability.

What changes now

The company's financial health has improved, moving from a loss-making entity to a profitable one. This positive performance may attract investor confidence. The re-appointment of Mr. Dopesh Raja Mulakala as Managing Director for a three-year term, effective April 18, 2026, ensures leadership stability and continuity in strategy.

Risks to watch

While the turnaround is positive, investors should monitor the company's ability to sustain this profitability in the coming quarters. Further growth in revenue and managing operational costs effectively will be crucial.

Peer comparison

(No specific peer comparison data was available in the filing.)

Context metrics (time-bound)

For the fiscal year ended March 31, 2026, Vanta Bioscience reported revenue of ₹1.8164 crore and a net profit of ₹0.1198 crore. This compares to FY2025 figures of ₹1.1274 crore in revenue and a net loss of ₹(2.6595) crore.

What to track next

Investors should keep an eye on Vanta Bioscience's subsequent quarterly results to confirm the sustainability of its profitability and continued revenue growth. The company's strategic initiatives under the re-appointed Managing Director will also be important to follow.